EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Updates in Lung Cancer Screening: A Decade of Evidence

Lori C Sakoda, Louise M Henderson

Seminars in Respiratory and Critical Care Medicine · 2025-10 · 46 (05) · 502-519

DOI: 10.1055/a-2701-9312 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Seminars in Respiratory and Critical Care Medicine, online erschienen am 16.10.2025. Verfasst von Lori C Sakoda und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Research, Kaiser Permanente Northern California, Pleasanton, California. Hauptthemen laut MEDLINE: Lung Neoplasms, Early Detection of Cancer, Mass Screening. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 215 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In this review, we summarize recent evidence from approximately the last 5 years across the lung cancer screening (LCS) care continuum. First, we review the results from the NELSON trial, from the extended follow-up of other LCS randomized controlled trials (RCTs), and from a meta-analysis of RCTs. Together, these RCTs reported a 16% relative reduction in lung cancer mortality for low-dose CT (LDCT) LCS versus non-LDCT controls. Next, we summarize updates to clinical guidelines and recommendations around LCS in the United States, noting the current debate around the use of time since quit as an eligibility criterion. We also discuss the implementation of LCS focusing on the following areas: (1) global landscape, (2) selection criteria and approach, (3) LCS program structure, (4) shared decision making, (5) smoking cessation, (6) LCS uptake, (7) American College of Radiology Lung Reporting and Data System, (8) annual LCS adherence, (9) screen-detected findings and management, (10) incidental findings and management, and (11) disparities. Lastly, we highlight emerging data and considerations for personalized LCS and new technologies, with an emphasis on risk prediction models, biomarkers, and artificial intelligence. This review highlights the latest changes to LCS and the ongoing need to monitor and evaluate LCS as it diffuses into clinical practice across various real-world settings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsEarly Detection of CancerMass ScreeningHumansTomography, X-Ray ComputedPractice Guidelines as TopicSmoking CessationRandomized Controlled Trials as TopicUnited States

Autor:innen und Institutionen

  • Division of Research, Kaiser Permanente Northern California, Pleasanton, California.
  • Department of Health Systems Science, Kaiser Permanente Bernard J. Tyson School of Medicine, Pasadena, California.
  • University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
  • Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina.

Förderung

  • NCI NIH HHS
  • NIH HHS
  • National Institutes of Health

Zitieren

APA

Sakoda, L. C., & Henderson, L. M. (2025). Updates in Lung Cancer Screening: A Decade of Evidence. Seminars in Respiratory and Critical Care Medicine, 46(05), 502-519. https://doi.org/10.1055/a-2701-9312

Vancouver

Sakoda LC, Henderson LM. Updates in Lung Cancer Screening: A Decade of Evidence. Seminars in Respiratory and Critical Care Medicine. 2025;46(05):502-519. doi:10.1055/a-2701-9312

BibTeX
@article{Sakoda2025,
  author = {Sakoda, Lori C and Henderson, Louise M},
  title = {Updates in Lung Cancer Screening: A Decade of Evidence},
  journal = {Seminars in Respiratory and Critical Care Medicine},
  year = {2025},
  volume = {46},
  number = {05},
  pages = {502--519},
  doi = {10.1055/a-2701-9312}
}
Kostenlos starten →